Prolaris for prostate cancer

There is widespread concern that the early detection of prostate cancer through screening programs has led to the overtreatment of localized disease.

Approximately 90% of all localized prostate cancer patients receive definitive treatment, including radical prostatectomy, radiation therapy, androgen deprivation therapy, or some combination. This occurs despite the high risk of treatment-related complications and the fact that the vast majority of prostate cancers do not cause death even when initial management is conservative.

It is estimated that $1.32 billion could be saved annually in the U.S. by avoiding unnecessary treatment of men who will never die of their prostate cancer.1 Risk stratification using typical prognostic factors continues to leave physicians and patients with uncertainty about the aggressiveness of prostate cancer, resulting in underutilization of active surveillance. Prolaris fills the need for a prognostic indicator that distinguishes between aggressive and indolent tumors more accurately than current clinical and pathologic features, enabling physicians to confidently tailor optimal treatment strategies for each patient.

1Aizer AA, Gu X, Chen M-H, et al. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. J Natl Compr Canc Netw 2015; 13:61-8.